Bronstein MD - Search Results

1

Prolactinomas and pregnancy.

Bronstein MD. Bronstein MD. Pituitary. 2005;8(1):31-8. doi: 10.1007/s11102-005-5083-4. Pituitary. 2005. PMID: 16411066 Review.

2

Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.

Passos VQ, Souza JJ, Musolino NR, Bronstein MD. Passos VQ, et al. Among authors: bronstein md. J Clin Endocrinol Metab. 2002 Aug;87(8):3578-82. doi: 10.1210/jcem.87.8.8722. J Clin Endocrinol Metab. 2002. PMID: 12161478

3

Medical management of pituitary adenomas: the special case of management of the pregnant woman.

Bronstein MD, Salgado LR, de Castro Musolino NR. Bronstein MD, et al. Pituitary. 2002;5(2):99-107. doi: 10.1023/a:1022364514971. Pituitary. 2002. PMID: 12675507 Review.

4

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Jallad RS, et al. Among authors: bronstein md. Clin Endocrinol (Oxf). 2005 Aug;63(2):168-75. doi: 10.1111/j.1365-2265.2005.02317.x. Clin Endocrinol (Oxf). 2005. PMID: 16060910

5

[Pituitary tumorigenesis].

Bronstein MD, Melmed S. Bronstein MD, et al. Arq Bras Endocrinol Metabol. 2005 Oct;49(5):615-25. doi: 10.1590/s0004-27302005000500003. Epub 2006 Jan 23. Arq Bras Endocrinol Metabol. 2005. PMID: 16444345 Review. Portuguese.

6

Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome.

Bronstein MD. Bronstein MD. Front Horm Res. 2006;35:129-134. doi: 10.1159/000094315. Front Horm Res. 2006. PMID: 16809928 Review.

7

Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.

da Rocha AA, Giorgi RR, de Sa SV, Correa-Giannella ML, Fortes MA, Cavaleiro AM, Machado MC, Cescato VA, Bronstein MD, Giannella-Neto D. da Rocha AA, et al. Among authors: bronstein md. Pituitary. 2006;9(2):83-92. doi: 10.1007/s11102-006-9277-1. Pituitary. 2006. PMID: 16832584

8

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Casanueva FF, et al. Among authors: bronstein md. Clin Endocrinol (Oxf). 2006 Aug;65(2):265-73. doi: 10.1111/j.1365-2265.2006.02562.x. Clin Endocrinol (Oxf). 2006. PMID: 16886971

9

Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.

Bronstein MD. Bronstein MD. Nat Clin Pract Endocrinol Metab. 2006 Mar;2(3):130-1. doi: 10.1038/ncpendmet0135. Nat Clin Pract Endocrinol Metab. 2006. PMID: 16932269 No abstract available.

10

PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.

Cristina C, Díaz-Torga GS, Goya RG, Kakar SS, Perez-Millán MI, Passos VQ, Giannella-Neto D, Bronstein MD, Becu-Villalobos D. Cristina C, et al. Among authors: bronstein md. Mol Cancer. 2007 Jan 12;6:4. doi: 10.1186/1476-4598-6-4. Mol Cancer. 2007. PMID: 17222350 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results